1. Hem
  2. Products
  3. Aspaveli
  4. About PNH
  5. Ongoing anaemia
Aspaveli - 0 - Aspaveli - SE

Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.1

Ongoing anaemia

PNH is a rare and potentially life-threatening disease characterised by the complement-mediated destruction of red blood cells, known as haemolysis.3,4

PNH results in a variety of complications, including anaemia, thrombosis and fatigue.3,4

Two types of haemolysis occur in PNH:

Ongoing Anaemia

C3-mediated EVH is the main cause of residual anaemia in PNH during treatment with C5 inhibitors.4

Discover the indicators of ongoing EVH

A combination of these haematologic indicators may suggest EVH:5,6

  • Below normal levels of Hb
  • Normal or slightly elevated LDH
  • Elevated ARC and/or elevated levels of bilirubin
Learn how ongoing anaemia occurs in PNH

References

1. Aspaveli (pegcetacoplan) Summary of Product Characteristics 08/2024. 2. Hillmen P et al. N Engl J Med. 2021;384:1028–1037. 3. Hill A et al. Nat Rev Dis Primers. 2017;3(18):17028. 4. Risitano AM et al. BJH. 2022;196:288–303. 5. Hill A et al. Haematologica. 2010;95(4):567–573. 6. Brodsky RA. Blood. 2014;124(18):2804–2811. 

PP-20361
Other sites
expand_less